New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of duvelisib (COPIKTRA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.
In addition, duvelisib (COPIKTRA) received accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Duvelisib (COPIKTRA) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.
“Each lymphoma patient’s experience is unique, and today’s approval offers patients with CLL/SLL and FL a new treatment option and a new opportunity for hope,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “We applaud the FDA, Verastem Oncology and the patients who participated in the clinical trials for their roles in advancing treatment options for people living with CLL/SLL and FL.”